Cite

HARVARD Citation

    Petrylak, D. et al. (2019). Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer. Prostate. 79 (6), pp. 604-613. [Online]. 
  
Back to record